Inactive Instrument

Analyst Reco. TCR2 Therapeutics Inc.

Equities

TCRR

US87808K1060

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Mizuho Securities Downgrades TCR2 Therapeutics to Neutral From Buy, Adjusts Price Target to $1.72 From $20	24/03/23	MT
Wedbush Adjusts TCR2 Therapeutics Price Target to $1.68 From $2.18, Maintains Neutral Rating	23/03/23	MT
Jefferies Downgrades TCR2 Therapeutics to Hold From Buy, Cuts Price Target to $3 From $18	09/03/23	MT
Truist Securities Downgrades TCR2 Therapeutics to Hold From Buy, Cuts Price Target to $3 From $8	07/03/23	MT
HC Wainwright Downgrades TCR2 Therapeutics to Neutral From Buy	07/03/23	MT
Wedbush Lowers TCR2 Therapeutics' Price Target to $2.18 From $4 on Heels of Adaptimmune Merger Announcement, Keeps Neutral Rating	07/03/23	MT
Piper Sandler Adjusts Price Target on TCR2 Therapeutics to $10 From $8, Maintains Overweight Rating	06/01/23	MT
EF Hutton Starts TCR2 Therapeutics at Hold With $2 Price Target	05/01/23	MT
HC Wainwright Trims Price Target on TCR2 Therapeutics to $13 From $14, Maintains Buy Rating	21/11/22	MT
SVB Leerink Adjusts Price Target on TCR2 Therapeutics to $2 From $3, Maintains Market Perform Rating	08/11/22	MT
Piper Sandler Adjusts TCR2 Therapeutics Price Target to $8 From $16, Retains Overweight Rating	08/11/22	MT
Truist Securities Lowers TCR2 Therapeutics' Price Target to $18 From $29, Maintains Buy Rating	23/08/22	MT
HC Wainwright Adjusts Price Target on TCR2 Therapeutics to $14 From $19, Reiterates Buy Rating	19/05/22	MT
Wedbush Adjusts Price Target for TCR2 Therapeutics to $4 From $8, Maintains Neutral Rating	12/05/22	MT
Piper Sandler Adjusts TCR2 Therapeutics Price Target to $15 From $23, Maintains Overweight Rating	12/05/22	MT
Goldman Sachs Adjusts TCR2 Therapeutics Price Target to $3 From $5, Maintains Neutral Rating	23/03/22	MT
Jefferies & Co Adjusts TCR2 Therapeutics Price Target to $19 From $24, Maintains Buy Rating	23/03/22	MT
SVB Leerink Adjusts TCR2 Therapeutics' Price Target to $3 from $7, Keeps Market Perform Rating	23/03/22	MT
SVB Leerink Adjusts TCR2 Therapeutics Price Target to $3 From $7, Maintains Market Perform Rating	22/03/22	MT
Piper Sandler Adjusts TCR2 Therapeutics Price Target to $23 From $26, Maintains Overweight Rating	22/03/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. TCR2 Therapeutics Inc.

Equities

TCRR

US87808K1060

Analyst Reco.

Filters